A recent study reveals that people who stop using blockbuster slimming jabs like Mounjaro or Wegovy may regain shed pounds far faster than those who stop conventional diet and exercise plans.
Research printed in a leading health publication demonstrates that while obese individuals frequently drop a large proportion of their total mass while undergoing treatment, the mass returns at an average rate of 0.8 kg per month after stopping.
"Users using these drugs should be informed of the risk of fast weight regain when the medication ends," warns researcher Dr. Susan Jebb.
That rate of regain means a return to pre-treatment mass in about one and a half years.
Analyzing Therapies
The analysis, which examined dozens of trials involving thousands of patients, compared the effects of GLP-1 agonists with older methods.
Scientists note that individuals who shed pounds through dieting typically have a slower creep back—around 100 grams monthly—once they finish.
Understanding the Fast Rebound
Experts propose the mechanism of the injections is key to understanding the accelerated regain.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Artificially providing GLP-1 levels far above than the body's typical production could lead to the system to produce less of its own natural hormone, and may also lessen responsiveness to its effects," explained Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this GLP-1 'fix' results in appetite is unsuppressed, making binge eating a significant risk."
An Ongoing Condition?
Medical guidelines recommend the jabs for people with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
Many experts contend that, due to the high risk of relapse, the treatment should be considered life-long.
This perspective is supported by drug manufacturers, who say that the findings "highlight the chronic nature of excess weight," similar to managing conditions like high blood pressure.
User Accounts
Individuals who have discontinued the jabs report a powerful return of hunger.
"I experienced a switch flipping and I was suddenly starving," recalled a patient.
The struggle is compounded if individuals have not developed lasting dietary or behavioural changes during treatment.
Growing Use
Recent estimates suggest that millions of people in the UK have tried weight-loss jabs in the past year, with interest being substantial.
- Adoption is greater among women compared to males.
- The 40s and 50s demographic shows the greatest usage rates.
- Many obtain the medications through private healthcare rather than the NHS.
Ultimately, researchers emphasize that while GLP-1 drugs are effective agents for weight loss, they are not a standalone fix and long-term success likely depends on combined lifestyle changes.
